Mylan Inc. is launching nevirapine tablets 200 mg, indicated for the combination antiretroviral (ARV) treatment of HIV-1 infection.


Mylan, Mylan Pharmaceuticals, nevirapine tablets, Viramune, generic version of Viramune, Heather Bresch, HIV/AIDS, HIV-1 infection, antiretroviral, ARV, generic ARVs, Mylan ARV product








































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan releases HIV/AIDS medication

May 23rd, 2012

PITTSBURGH – Mylan Inc. is launching nevirapine tablets 200 mg, indicated for the combination antiretroviral (ARV) treatment of HIV-1 infection.

The company said Wednesday that its Mylan Pharmaceuticals Inc. has begun shipping the medication after receiving final approval from the Food and Drug Administration.

According to Mylan, the product is the generic version of Boehringer Ingelheim's Viramune.

"The launch of nevirapine tablets, 200 mg, in the U.S. further expands the reach of Mylan's global ARV portfolio," commented Mylan chief executive officer Heather Bresch. "Currently, approximately one-third of HIV/AIDS patients in developing countries depend on a Mylan ARV product, and the company is committed to continue bringing affordable, high-quality generic ARVs to market in the U.S."

Nevirapine tablets 200 mg had U.S. sales of about $116.6 million for the 12 months ended March 31, according to IMS Health figures reported by Mylan.

Advertisement